Table 2.
Laboratory findings at presentation.
Case | WBC | Hb | Platelet | LDH | BUN | Cr | Crmax | ADAMTS13 | Plasma exchange |
---|---|---|---|---|---|---|---|---|---|
×109/L | g/L | ×109/L | U/L | mg/dL | mg/dL | mg/dL | % | Number of sessions | |
1 | 10.1 | 125 | 52 | 3,330 | 76 | 2.6 | 6.5 on day 3 | 86 | 17 for 19 days |
2∗ | 12.5 | 85 | 99 | 1,271 | 39 | 3.37 | — | 55 | 15 for 18 days |
3 | 10.48 | 95 | 96 | 1,471 | 55 | 4.84 | 5.99 on day 32 | 79 | 1 for 1 day |
4-1 | 13.59 | 71 | 65 | 910 | 28 | 2.51 | 4.02 on day 17 | 85 | 6 for 6 days |
4-2 | 5.07 | 84 | 63 | 770 | 46 | 5.52 | 6.86 on day 2 | — | 0 |
5∗∗ | 2.69 | 111 | 57 | 892 | 71 | 5.43 | 5.53 on day 2 | 74 | 5 for 6 days |
*The patient was on hemodialysis at the time of transfer.
∗∗The patient received her last dose of gemcitabine and carboplatin 3 weeks before presentation.
Normal ADAMTS13 activity, >67%; Crmax: maximal serum creatinine.